1. Home
  2. CGON vs CMBT Comparison

CGON vs CMBT Comparison

Compare CGON & CMBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGON
  • CMBT
  • Stock Information
  • Founded
  • CGON 2010
  • CMBT 1989
  • Country
  • CGON United States
  • CMBT Belgium
  • Employees
  • CGON N/A
  • CMBT N/A
  • Industry
  • CGON
  • CMBT
  • Sector
  • CGON
  • CMBT
  • Exchange
  • CGON NYSE
  • CMBT NYSE
  • Market Cap
  • CGON 2.0B
  • CMBT 1.9B
  • IPO Year
  • CGON 2024
  • CMBT N/A
  • Fundamental
  • Price
  • CGON $26.91
  • CMBT $9.00
  • Analyst Decision
  • CGON Strong Buy
  • CMBT
  • Analyst Count
  • CGON 11
  • CMBT 0
  • Target Price
  • CGON $63.30
  • CMBT N/A
  • AVG Volume (30 Days)
  • CGON 979.0K
  • CMBT 93.6K
  • Earning Date
  • CGON 08-07-2025
  • CMBT 08-07-2025
  • Dividend Yield
  • CGON N/A
  • CMBT N/A
  • EPS Growth
  • CGON N/A
  • CMBT N/A
  • EPS
  • CGON N/A
  • CMBT 2.16
  • Revenue
  • CGON $662,000.00
  • CMBT $934,913,000.00
  • Revenue This Year
  • CGON N/A
  • CMBT $5.05
  • Revenue Next Year
  • CGON $21,843.29
  • CMBT $24.22
  • P/E Ratio
  • CGON N/A
  • CMBT $4.29
  • Revenue Growth
  • CGON 224.51
  • CMBT N/A
  • 52 Week Low
  • CGON $14.80
  • CMBT $7.65
  • 52 Week High
  • CGON $40.47
  • CMBT $18.43
  • Technical
  • Relative Strength Index (RSI)
  • CGON 54.12
  • CMBT 41.33
  • Support Level
  • CGON $25.14
  • CMBT $9.18
  • Resistance Level
  • CGON $27.09
  • CMBT $9.46
  • Average True Range (ATR)
  • CGON 1.50
  • CMBT 0.20
  • MACD
  • CGON -0.04
  • CMBT -0.03
  • Stochastic Oscillator
  • CGON 53.56
  • CMBT 5.44

About CGON CG ONCOLOGY INC

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

About CMBT EURONAV

CMB.Tech NV owns and operates a fleet of vessels for international maritime shipping and storage of crude oil and petroleum products. It generate a large parts of their revenue from voyage charters, including vessels in pools that predominantly perform voyage charters. The company organizes itself into three divisons: the Marine division, the H2 Infra division and the H2 Industry division. The Marine Division derives maximum revenue.

Share on Social Networks: